Yoshihito Ueno
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Yoshihito Ueno has a total of 120 co-authors. Here are the top co-authors by number of shared publications:
- Yukio Kitade
Gifu University
13 shared publications - Yoshiaki Kitamura
Department of Life Science and Chemistry, Graduate School of Natural Science and Technology, Gifu University, 1-1 Yanagido, Gifu 501-1193, Japan
9 shared publications Yusuke Maeda
Course of Applied Life Science, Faculty of Applied Biological Sciences, Gifu University, Gifu, Japan
9 shared publicationsRyohei Kajino
United Graduate School of Agricultural Science, Gifu University, Japan
7 shared publicationsAkash Chandela
Course of Applied Life Science, Faculty of Applied Biological Sciences Gifu University 1-1 Yanagido Gifu 501-1193 Japan
6 shared publicationsKayo Yoshikawa
Department of Biomolecular Science, Faculty of Engineering, Gifu University, 1-1 Yanagido, Gifu 501-1193, Japan
6 shared publications
Latest Publications
- Open Access
- 1 July 2026
- Published by American Chemical Society (ACS) in ACS Omega
- Vol. 11 (27) , 40426-40440
1′-Sugar-Tethered Cholesterol-Modified siRNAs with Variable Linker Lengths for Carrier-Free Delivery and Enhanced RNAi Efficiency
- 1 July 2026
- Published by American Chemical Society (ACS) in ACS Omega
- Vol. 11 (27) , 40426-40440
Open Access1′-Sugar-Tethered Cholesterol-Modified siRNAs with Variable Linker Lengths for Carrier-Free Delivery and Enhanced RNAi Efficiency
- Open Access
- 14 December 2025
- Published by American Chemical Society (ACS) in ACS Omega
- Vol. 10 (51) , 62813-62827
Ligand Valency and Linker Design Dictate the Efficacy of CI-M6PR-Mediated Targeted Delivery of M6P–siRNA Conjugates
Targeted delivery of small interfering RNAs (siRNAs) to nonhepatic tissues remains a major challenge in RNAi therapeutics owing to inefficient cellular uptake and off-target effects. In this study, mannose-6-phosphate (M6P)-conjugated siRNAs are developed to target the cation-independent M6P receptor (CI-M6PR/IGF2R), which is overexpressed in various cancers, including chronic myeloid leukemia (CML). Several mono-, di-, and tetravalent M6P–siRNA conjugates are synthesized via solid-phase methods using either flexible hexanediol or rigid proline-based linkers. Thermal melting analysis indicated that M6P conjugation modestly reduced duplex stability, with high-valence constructs and those containing more flexible linkers being particularly affected. By contrast, rigid proline linkers mitigated destabilization. Circular dichroism spectroscopy confirmed that the native A-form RNA structure was maintained after M6P conjugation, while in vitro gene silencing studies in CI-M6PR-positive K562 cells targeting KNTC2 mRNA demonstrated that ligand valency and linker rigidity significantly influenced the activity under transfection-free conditions. Tetravalent siRNA 7 (partially proline-linked) achieved the most efficient knockdown (∼36% reduction in KNTC2 mRNA), whereas the reduction in the activity of tetravalent siRNA 5 (fully hexanediol-linked) was similar to that of the divalent constructs, likely owing to impaired receptor engagement. Flow cytometry analysis further established that this superior activity was attributable to the markedly higher cellular uptake of siRNA 7 relative to the other conjugates. Electroporation experiments confirmed that all siRNA variants retained RNAi activity, indicating that delivery efficiency, rather than functional impairment, is responsible for the observed activity differences. These findings illustrate the pivotal role of ligand valency and linker architecture in optimizing CI-M6PR-targeted siRNA delivery and provide a framework for designing ligand-conjugated siRNA therapeutics against CI-M6PR-expressing tumors.
- 14 December 2025
- Published by American Chemical Society (ACS) in ACS Omega
- Vol. 10 (51) , 62813-62827
Open AccessLigand Valency and Linker Design Dictate the Efficacy of CI-M6PR-Mediated Targeted Delivery of M6P–siRNA Conjugates
Targeted delivery of small interfering RNAs (siRNAs) to nonhepatic tissues remains a major challenge in RNAi therapeutics owing to inefficient cellular uptake and off-target effects. In this study, mannose-6-phosphate (M6P)-conjugated siRNAs are developed to target the cation-independent M6P receptor (CI-M6PR/IGF2R), which is overexpressed in various cancers, including chronic myeloid leukemia (CML). Several mono-, di-, and tetravalent M6P–siRNA conjugates are synthesized via solid-phase methods using either flexible hexanediol or rigid proline-based linkers. Thermal melting analysis indicated that M6P conjugation modestly reduced duplex stability, with high-valence constructs and those containing more flexible linkers being particularly affected. By contrast, rigid proline linkers mitigated destabilization. Circular dichroism spectroscopy confirmed that the native A-form RNA structure was maintained after M6P conjugation, while in vitro gene silencing studies in CI-M6PR-positive K562 cells targeting KNTC2 mRNA demonstrated that ligand valency and linker rigidity significantly influenced the activity under transfection-free conditions. Tetravalent siRNA 7 (partially proline-linked) achieved the most efficient knockdown (∼36% reduction in KNTC2 mRNA), whereas the reduction in the activity of tetravalent siRNA 5 (fully hexanediol-linked) was similar to that of the divalent constructs, likely owing to impaired receptor engagement. Flow cytometry analysis further established that this superior activity was attributable to the markedly higher cellular uptake of siRNA 7 relative to the other conjugates. Electroporation experiments confirmed that all siRNA variants retained RNAi activity, indicating that delivery efficiency, rather than functional impairment, is responsible for the observed activity differences. These findings illustrate the pivotal role of ligand valency and linker architecture in optimizing CI-M6PR-targeted siRNA delivery and provide a framework for designing ligand-conjugated siRNA therapeutics against CI-M6PR-expressing tumors.
- Open Access
Synthesis and Application of 4′-C-[(N-alkyl)aminoethyl]thymidine Analogs for Optimizing Oligonucleotide Properties
Gapmer-type antisense oligonucleotides (ASOs) are an emerging class of therapeutic agents that directly inhibit pathogenic mRNA. In this study, three new 4′-C-substituted thymidine analogs were generated using a synthetic strategy recently established by our group, namely, 4′-C-(N-ethyl) aminoethyl (4′-EAE-T), 4′-C-(N-butyl) aminoethyl (4′-BAE-T), and 4′-C-(N-octyl) aminoethyl (4′-OAE-T). Their properties were evaluated and compared with those of previously reported analogs, including 4′-C-aminoethyl (4′-AE-T) and 4′-C-(N-methyl) aminoethyl (4′-MAE-T). The novel nucleoside analogs were subsequently incorporated into gapmer-type ASOs featuring phosphorothioate (PS) linkages and locked nucleic acids (LNAs) in the wing regions. The incorporation of 4′-EAE-T and 4′-BAE-T analogs resulted in RNA binding affinities similar to that of the previously reported 4′-MAE-T analog, whereas a marked decrease in RNA affinity was noted for 4′-OAE-T, however, this reduction was mitigated when combined with other chemical modifications. Furthermore, the structural modifications conferred enhanced nuclease resistance under bovine serum conditions, with 4′-EAE-T resulting in the highest stability, followed by 4′-BAE-T and 4′-OAE-T. Additionally, oligonucleotides modified with the developed analogs preserved their RNase H cleavage susceptibility, albeit inducing minor alterations in the cleavage pattern. Finally, the oligonucleotides were applied in a gene silencing experiment targeting the KRAS gene, conducted without the use of transfection agents, displaying gene silencing activities comparable to that of the control, with the exception of the 4′-OAE-modified nucleotide, which exhibited low activity.
Open AccessSynthesis and Application of 4′-C-[(N-alkyl)aminoethyl]thymidine Analogs for Optimizing Oligonucleotide Properties
Gapmer-type antisense oligonucleotides (ASOs) are an emerging class of therapeutic agents that directly inhibit pathogenic mRNA. In this study, three new 4′-C-substituted thymidine analogs were generated using a synthetic strategy recently established by our group, namely, 4′-C-(N-ethyl) aminoethyl (4′-EAE-T), 4′-C-(N-butyl) aminoethyl (4′-BAE-T), and 4′-C-(N-octyl) aminoethyl (4′-OAE-T). Their properties were evaluated and compared with those of previously reported analogs, including 4′-C-aminoethyl (4′-AE-T) and 4′-C-(N-methyl) aminoethyl (4′-MAE-T). The novel nucleoside analogs were subsequently incorporated into gapmer-type ASOs featuring phosphorothioate (PS) linkages and locked nucleic acids (LNAs) in the wing regions. The incorporation of 4′-EAE-T and 4′-BAE-T analogs resulted in RNA binding affinities similar to that of the previously reported 4′-MAE-T analog, whereas a marked decrease in RNA affinity was noted for 4′-OAE-T, however, this reduction was mitigated when combined with other chemical modifications. Furthermore, the structural modifications conferred enhanced nuclease resistance under bovine serum conditions, with 4′-EAE-T resulting in the highest stability, followed by 4′-BAE-T and 4′-OAE-T. Additionally, oligonucleotides modified with the developed analogs preserved their RNase H cleavage susceptibility, albeit inducing minor alterations in the cleavage pattern. Finally, the oligonucleotides were applied in a gene silencing experiment targeting the KRAS gene, conducted without the use of transfection agents, displaying gene silencing activities comparable to that of the control, with the exception of the 4′-OAE-modified nucleotide, which exhibited low activity.
- Open Access
- 10 December 2024
- Published by Royal Society of Chemistry (RSC) in RSC Advances
- Vol. 14 (53) , 39148-39162
Application of 4′- C -α-aminoethoxy-2′- O -methyl-5-propynyl-uridine for antisense therapeutics
Antisense oligonucleotides containing 4′- C -α-aminoethoxy-2′- O -methyl-5-propynyl-uridine showed superior thermal stability and nuclease resistance and could efficiently activate RNase H-mediated antisense in vitro in the presence of native DNA gaps.
- 10 December 2024
- Published by Royal Society of Chemistry (RSC) in RSC Advances
- Vol. 14 (53) , 39148-39162
Open AccessApplication of 4′- C -α-aminoethoxy-2′- O -methyl-5-propynyl-uridine for antisense therapeutics
Antisense oligonucleotides containing 4′- C -α-aminoethoxy-2′- O -methyl-5-propynyl-uridine showed superior thermal stability and nuclease resistance and could efficiently activate RNase H-mediated antisense in vitro in the presence of native DNA gaps.
- Open Access
- 9 July 2024
- Published by Elsevier in Results in Chemistry
- Vol. 9
Novel synthesis and evaluation of oligonucleotides containing (S)-5′-C-aminopropyl-modified thymidine analogs for RNase H-dependent antisense therapy
- 9 July 2024
- Published by Elsevier in Results in Chemistry
- Vol. 9
Open AccessNovel synthesis and evaluation of oligonucleotides containing (S)-5′-C-aminopropyl-modified thymidine analogs for RNase H-dependent antisense therapy
- 18 June 2024
- Published by Wiley in ChemistrySelect
- Vol. 9 (23)
Synthesis and Evaluation of 4′‐ C ‐( S ) and 4′‐ C ‐( R )‐2‐Aminopropoxy−Thymidine‐Modified DNAs for Thermal Stability, RNase H Digestion, and Nuclease Resistance
Antisense oligonucleotides (ASOs) have been developed as potential therapeutic agents for genetic disorders and various life‐threatening conditions. This class of therapeutics facilitates the treatment of the currently undruggable targets. However, their low stability and poor activity must be overcome by developing new analogs with improved functions. Therefore, in this study, we synthesized 4′‐ C ‐( S )‐ and 4′‐ C ‐( R )‐2‐aminopropoxy−thymidine and investigated the stability of the modified oligonucleotides containing these analogs. Interestingly, both analogs responded differently to thermal denaturation, with the former exhibiting good stability closer to that of the unmodified oligonucleotide and the latter exhibiting slight thermal destabilization. Notably, DNA/RNA heteroduplexes modified with these analogs elicited RNase H activity by degrading the heteroduplexes upon treatment. In addition, the serum stability of the modified oligodeoxynucleotides was significantly enhanced by the introduction of these analogs. Overall, our findings highlight the potential application of these analogs as ASO therapeutic candidates.
- 18 June 2024
- Published by Wiley in ChemistrySelect
- Vol. 9 (23)
Synthesis and Evaluation of 4′‐ C ‐( S ) and 4′‐ C ‐( R )‐2‐Aminopropoxy−Thymidine‐Modified DNAs for Thermal Stability, RNase H Digestion, and Nuclease Resistance
Antisense oligonucleotides (ASOs) have been developed as potential therapeutic agents for genetic disorders and various life‐threatening conditions. This class of therapeutics facilitates the treatment of the currently undruggable targets. However, their low stability and poor activity must be overcome by developing new analogs with improved functions. Therefore, in this study, we synthesized 4′‐ C ‐( S )‐ and 4′‐ C ‐( R )‐2‐aminopropoxy−thymidine and investigated the stability of the modified oligonucleotides containing these analogs. Interestingly, both analogs responded differently to thermal denaturation, with the former exhibiting good stability closer to that of the unmodified oligonucleotide and the latter exhibiting slight thermal destabilization. Notably, DNA/RNA heteroduplexes modified with these analogs elicited RNase H activity by degrading the heteroduplexes upon treatment. In addition, the serum stability of the modified oligodeoxynucleotides was significantly enhanced by the introduction of these analogs. Overall, our findings highlight the potential application of these analogs as ASO therapeutic candidates.
- 1 February 2024
- Published by Elsevier in Bioorganic Chemistry
- Vol. 144, 107143
Properties and synergistic effects of a nonionic backbone and aminoalkyl modified nucleosides in RNAs
- 1 February 2024
- Published by Elsevier in Bioorganic Chemistry
- Vol. 144, 107143
Properties and synergistic effects of a nonionic backbone and aminoalkyl modified nucleosides in RNAs
- Open Access
- 21 August 2023
- Published by Royal Society of Chemistry (RSC) in RSC Advances
- Vol. 13 (36) , 25169-25181
Non-terminal conjugation of small interfering RNAs with spermine improves duplex binding and serum stability with position-specific incorporation
The conjugation of small interfering RNAs (siRNAs) has been studied using lipid and ligand conjugates for efficient delivery. However, most conjugates have been inserted at the terminal position; very few have been inserted at non-terminal positions. Herein, we synthesized a 4′-C-propyllevulinate-2′-O-methyluridine analog for non-terminal conjugation of spermine into the passenger strand of siRNA. Solid-phase oligonucleotide synthesis using this analog was successful, with the conjugation of one or two spermine molecules. The siRNAs conjugated with spermine displayed improved thermodynamic stability and resistance against nucleases, which depended on the site of conjugation in each case. Circular dichroism spectroscopy revealed that the A-type helical structure of the RNA duplex was not altered by these modifications. However, the gene-silencing activity of conjugated siRNAs was reduced and further decreased when the number of spermine molecules was increased. Hence, this work supplies valuable information and provides scope for the further development of drug-delivery systems through non-terminal conjugation.
- 21 August 2023
- Published by Royal Society of Chemistry (RSC) in RSC Advances
- Vol. 13 (36) , 25169-25181
Open AccessNon-terminal conjugation of small interfering RNAs with spermine improves duplex binding and serum stability with position-specific incorporation
The conjugation of small interfering RNAs (siRNAs) has been studied using lipid and ligand conjugates for efficient delivery. However, most conjugates have been inserted at the terminal position; very few have been inserted at non-terminal positions. Herein, we synthesized a 4′-C-propyllevulinate-2′-O-methyluridine analog for non-terminal conjugation of spermine into the passenger strand of siRNA. Solid-phase oligonucleotide synthesis using this analog was successful, with the conjugation of one or two spermine molecules. The siRNAs conjugated with spermine displayed improved thermodynamic stability and resistance against nucleases, which depended on the site of conjugation in each case. Circular dichroism spectroscopy revealed that the A-type helical structure of the RNA duplex was not altered by these modifications. However, the gene-silencing activity of conjugated siRNAs was reduced and further decreased when the number of spermine molecules was increased. Hence, this work supplies valuable information and provides scope for the further development of drug-delivery systems through non-terminal conjugation.
- 10 May 2023
- Published by Elsevier in Bioorganic & Medicinal Chemistry
- Vol. 87, 117317
Synthesis and characterization of novel (S)-5′-C-aminopropyl-2′-fluorouridine modified oligonucleotides as therapeutic siRNAs
- 10 May 2023
- Published by Elsevier in Bioorganic & Medicinal Chemistry
- Vol. 87, 117317
Synthesis and characterization of novel (S)-5′-C-aminopropyl-2′-fluorouridine modified oligonucleotides as therapeutic siRNAs
- Open Access
Antisense Gapmers with LNA-Wings and (S)-5′-C-Aminopropyl-2′-arabinofluoro-nucleosides Could Efficiently Suppress the Expression of KNTC2
Previously reported (S)-5′-C-aminopropyl-2′-arabinofluoro-thymidine (5ara-T) and newly synthesized (S)-5′-C-aminopropyl-2′-arabinofluoro-5-methyl-cytidine (5ara-MeC) analogs were incorporated into a series of antisense gapmers containing multiple phosphorothioate (PS) linkages and locked nucleic acids (LNAs) in their wing regions. The functional properties of the gapmers were further evaluated in vitro. Compared with the positive control, for the LNA-wing full PS gapmer without 5ara modification, it was revealed that each gapmer could have a high affinity and be thermally stable under biological conditions. Although the cleavage pattern was obviously changed; gapmers with 5ara modification could still efficiently activate E. coli RNase H1. In addition, incorporating one 5ara modification into the two phosphodiester linkages could reverse the destabilization in enzymatic hydrolysis caused by fewer PS linkages. In vitro cellular experiments were also performed, and the Lipofectamine® 2000 (LFA)+ group showed relatively higher antisense activity than the LFA-free group. KN5ara-10, which contains fewer PS linkages, showed similar or slightly better antisense activity than the corresponding full PS-modified KN5ara-3. Hence, KN5ara-10 may be the most promising candidate for KNTC2-targeted cancer therapy.
Open AccessAntisense Gapmers with LNA-Wings and (S)-5′-C-Aminopropyl-2′-arabinofluoro-nucleosides Could Efficiently Suppress the Expression of KNTC2
Previously reported (S)-5′-C-aminopropyl-2′-arabinofluoro-thymidine (5ara-T) and newly synthesized (S)-5′-C-aminopropyl-2′-arabinofluoro-5-methyl-cytidine (5ara-MeC) analogs were incorporated into a series of antisense gapmers containing multiple phosphorothioate (PS) linkages and locked nucleic acids (LNAs) in their wing regions. The functional properties of the gapmers were further evaluated in vitro. Compared with the positive control, for the LNA-wing full PS gapmer without 5ara modification, it was revealed that each gapmer could have a high affinity and be thermally stable under biological conditions. Although the cleavage pattern was obviously changed; gapmers with 5ara modification could still efficiently activate E. coli RNase H1. In addition, incorporating one 5ara modification into the two phosphodiester linkages could reverse the destabilization in enzymatic hydrolysis caused by fewer PS linkages. In vitro cellular experiments were also performed, and the Lipofectamine® 2000 (LFA)+ group showed relatively higher antisense activity than the LFA-free group. KN5ara-10, which contains fewer PS linkages, showed similar or slightly better antisense activity than the corresponding full PS-modified KN5ara-3. Hence, KN5ara-10 may be the most promising candidate for KNTC2-targeted cancer therapy.